Publication list - Publika - Scientific publications from Oslo University Hospital

Publications by Terje Rolf Pedersen

196 publications found

Original articles

Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B, CTT Collaboration secretariat, Armitage J, Baigent C, Barnes E, Blackwell L, Collins R, Davies K, Emberson J, Fulcher J, Halls H, Herrington WG, Holland L et al. (2024)
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model
Br J Gen Pract, 74 (740), e189-98 (in press)
DOI 10.3399/BJGP.2023.0198, PubMed 38373851

Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, Lu C, Tay L, Deedwania PC, Siu CW, Lira Pineda A, Choi D, Charng MJ, Amerena J, Wan Ahmad WA, Chopra VK, Pedersen TR, Giugliano RP, Sabatine MS, FOURIER Study Group (2021)
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial
Circ J, 85 (11), 2063-2070
DOI 10.1253/circj.CJ-20-1051, PubMed 33980763

Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP (2021)
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial
JAMA Cardiol, 6 (2), 139-147
DOI 10.1001/jamacardio.2020.3151, PubMed 32785614

Vallejo-Vaz AJ, Packard CJ, Ference BA, Santos RD, Kastelein JJP, Stein EA, Catapano AL, Pedersen TR, Watts GF, Ray KK (2021)
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial
Atherosclerosis, 320, 1-9
DOI 10.1016/j.atherosclerosis.2021.01.003, PubMed 33497862

Landmesser U, Pirillo A, Farnier M, Jukema JW, Laufs U, Mach F, Masana L, Pedersen TR, Schiele F, Steg G, Tubaro M, Zaman A, Zamorano P, Catapano AL (2020)
Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project
Atheroscler Suppl, 42, e49-e58
DOI 10.1016/j.atherosclerosissup.2021.01.009, PubMed 33589224

Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, Ferreira J, Kurtz CE, Wang H, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP (2020)
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial
JAMA Cardiol, 5 (8), 952-957
DOI 10.1001/jamacardio.2020.0882, PubMed 32432684

Wiviott SD, Giugliano RP, Morrow DA, De Ferrari GM, Lewis BS, Huber K, Kuder JF, Murphy SA, Forni DM, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS (2020)
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial
JAMA Cardiol, 5 (7), 787-793
DOI 10.1001/jamacardio.2020.0764, PubMed 32347885

Bergmark BA, O'Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Ceška R, Gouni-Berthold I, Jensen HK, Tokgozoglu SL, Mach F, Huber K, Gaciong Z, Lewis BS, Schiele F, Jukema JW, Pedersen TR, Giugliano RP, Sabatine MS (2020)
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
JAMA Cardiol, 5 (6), 709-713
DOI 10.1001/jamacardio.2020.0728, PubMed 32347887

Gencer B, Mach F, Guo J, Im K, Ruzza A, Wang H, Kurtz CE, Pedersen TR, Keech AC, Ott BR, Sabatine MS, Giugliano RP, FOURIER Investigators (2020)
Cognition After Lowering LDL-Cholesterol With Evolocumab
J Am Coll Cardiol, 75 (18), 2283-2293
DOI 10.1016/j.jacc.2020.03.039, PubMed 32381158

Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, Murphy SA, Wasserman SM, Honarpour N, Wang H, Lira Pineda A, Sabatine MS, FOURIER Investigators (2020)
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
Stroke, 51 (5), 1546-1554
DOI 10.1161/STROKEAHA.119.027759, PubMed 32312223

Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS (2020)
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Circulation, 141 (20), 1600-1607
DOI 10.1161/CIRCULATIONAHA.120.046397, PubMed 32223429

Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, Wang H, Knusel B, Sabatine MS, O'Donoghue ML (2020)
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
Eur J Prev Cardiol, 28 (8), 805-812
DOI 10.1177/2047487320902750, PubMed 34298555

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Eur Heart J, 41 (1), 111-188
DOI 10.1093/eurheartj/ehz455, PubMed 31504418

Marston NA, Kamanu FK, Nordio F, Gurmu Y, Roselli C, Sever PS, Pedersen TR, Keech AC, Wang H, Lira Pineda A, Giugliano RP, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT (2019)
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
Circulation, 141 (8), 616-623
DOI 10.1161/CIRCULATIONAHA.119.043805, PubMed 31707849

Greve AM, Bang CN, Boman K, Egstrup K, Kesäniemi YA, Ray S, Pedersen TR, Wachtell K (2019)
Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis
Am J Cardiol, 124 (11), 1736-1740
DOI 10.1016/j.amjcard.2019.08.037, PubMed 31586530

Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MS (2019)
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial
JAMA Cardiol, 4 (7), 613-619
DOI 10.1001/jamacardio.2019.0886, PubMed 31116355

Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP, FOURIER Steering Committee and Investigators (2019)
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
J Am Coll Cardiol, 73 (23), 2961-2970
DOI 10.1016/j.jacc.2019.03.513, PubMed 31196453

O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
Circulation, 139 (12), 1483-1492
DOI 10.1161/CIRCULATIONAHA.118.037184, PubMed 30586750

Qamar A, Giugliano RP, Keech AC, Kuder JF, Murphy SA, Kurtz CE, Wasserman SM, Sever PS, Pedersen TR, Sabatine MS (2019)
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data
JAMA Cardiol, 4 (1), 59-63
DOI 10.1001/jamacardio.2018.4178, PubMed 30540337

Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Lancet, 392 (10155), 1311-1320
DOI 10.1016/S0140-6736(18)31652-0, PubMed 30293769

Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE (2018)
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Clin Cardiol, 41 (10), 1281-1288
DOI 10.1002/clc.23055, PubMed 30125052

Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR (2018)
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
Circulation, 138 (8), 756-766
DOI 10.1161/CIRCULATIONAHA.118.034309, PubMed 29626068

Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceška R, López-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, Sever PS, Keech AC, Pedersen TR, Sabatine MS (2018)
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial
JAMA Cardiol, 3 (8), 749-753
DOI 10.1001/jamacardio.2018.1533, PubMed 29898218

Thorolfsdottir RB, Sveinbjornsson G, Sulem P, Nielsen JB, Jonsson S, Halldorsson GH, Melsted P, Ivarsdottir EV, Davidsson OB, Kristjansson RP, Thorleifsson G, Helgadottir A, Gretarsdottir S, Norddahl G, Rajamani S, Torfason B, Valgardsson AS, Sverrisson JT, Tragante V, Holmen OL, Asselbergs FW, Roden DM, Darbar D, Pedersen TR, Sabatine MS et al. (2018)
Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation
Commun Biol, 1, 68
DOI 10.1038/s42003-018-0068-9, PubMed 30271950

Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS (2018)
Inflammatory and Cholesterol Risk in the FOURIER Trial
Circulation, 138 (2), 131-140
DOI 10.1161/CIRCULATIONAHA.118.034032, PubMed 29530884

Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen TR, Baigent C, Collins R, Landray M, Armitage J, HPS2-THRIVE Collaborative Group (2018)
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Circ Genom Precis Med, 11 (2), e001696
DOI 10.1161/CIRCGEN.117.001696, PubMed 29449329

Greve AM, Bang CN, Boman K, Egstrup K, Forman JL, Kesäniemi YA, Ray S, Pedersen TR, Best P, Rajamannan NM, Wachtell K (2017)
Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study)
Am J Cardiol, 121 (6), 739-745
DOI 10.1016/j.amjcard.2017.12.011, PubMed 29361285

Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS (2017)
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
JAMA Cardiol, 2 (12), 1385-1391
DOI 10.1001/jamacardio.2017.3944, PubMed 29117276

Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS (2017)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Circulation, 137 (4), 338-350
DOI 10.1161/CIRCULATIONAHA.117.032235, PubMed 29133605

Thorolfsdottir RB, Sveinbjornsson G, Sulem P, Helgadottir A, Gretarsdottir S, Benonisdottir S, Magnusdottir A, Davidsson OB, Rajamani S, Roden DM, Darbar D, Pedersen TR, Sabatine MS, Jonsdottir I, Arnar DO, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson K (2017)
A Missense Variant in PLEC Increases Risk of Atrial Fibrillation
J Am Coll Cardiol, 70 (17), 2157-2168
DOI 10.1016/j.jacc.2017.09.005, PubMed 29050564

Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS (2017)
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
JAMA Cardiol, 2 (10), 1069-1078
DOI 10.1001/jamacardio.2017.2762, PubMed 28832867

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Lancet Diabetes Endocrinol, 5 (12), 941-950
DOI 10.1016/S2213-8587(17)30313-3, PubMed 28927706

Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS, FOURIER Investigators (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Lancet, 390 (10106), 1962-1971
DOI 10.1016/S0140-6736(17)32290-0, PubMed 28859947

Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR, EBBINGHAUS Investigators (2017)
Cognitive Function in a Randomized Trial of Evolocumab
N Engl J Med, 377 (7), 633-643
DOI 10.1056/NEJMoa1701131, PubMed 28813214

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
N Engl J Med, 376 (18), 1713-1722
DOI 10.1056/NEJMoa1615664, PubMed 28304224

Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E (2017)
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
J Am Coll Cardiol, 69 (8), 911-921
DOI 10.1016/j.jacc.2016.11.070, PubMed 28231942

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Monique Verschuren WM, Vlachopoulos C, Wood DA, Luis Zamorano J, Additional Contributor, Cooney MT (2017)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Rev Esp Cardiol (Engl Ed), 70 (2), 115
DOI 10.1016/j.rec.2017.01.002, PubMed 29389351

Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman SM, Ott BR, EBBINGHAUS Investigators (2017)
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial
Clin Cardiol, 40 (2), 59-65
DOI 10.1002/clc.22678, PubMed 28207168

Authors/Task Force Members:, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR)
Atherosclerosis, 253, 281-344
DOI 10.1016/j.atherosclerosis.2016.08.018, PubMed 27594540

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, ESC Scientific Document Group (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Eur Heart J, 37 (39), 2999-3058
DOI 10.1093/eurheartj/ehw272, PubMed 27567407

Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesäniemi YA, Pedersen TR, Willenheimer R, Wachtell K (2016)
Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS)
Circulation, 134 (6), 455-68
DOI 10.1161/CIRCULATIONAHA.115.021213, PubMed 27486164

Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A, TNT, CARDS and IDEAL Steering Committees and Investigators (2016)
Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes
Int J Cardiol, 222, 548-556
DOI 10.1016/j.ijcard.2016.07.201, PubMed 27513651

Ikdahl E, Rollefstad S, Hisdal J, Olsen IC, Pedersen TR, Kvien TK, Semb AG (2016)
Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study
PLoS One, 11 (4), e0153440
DOI 10.1371/journal.pone.0153440, PubMed 27093159

Pedersen TR (2016)
The Success Story of LDL Cholesterol Lowering
Circ Res, 118 (4), 721-31
DOI 10.1161/CIRCRESAHA.115.306297, PubMed 26892969

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL (2016)
[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]
Kardiol Pol, 74 (11), 1234-1318
DOI 10.5603/KP.2016.0157, PubMed 27910077

Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, Wasserman SM, Scott R, Sever PS, Pedersen TR (2015)
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
Am Heart J, 173, 94-101
DOI 10.1016/j.ahj.2015.11.015, PubMed 26920601

Rollefstad S, Ikdahl E, Hisdal J, Kvien TK, Pedersen TR, Semb AG (2015)
Association of Chest Pain and Risk of Cardiovascular Disease with Coronary Atherosclerosis in Patients with Inflammatory Joint Diseases
Front Med (Lausanne), 2, 80
DOI 10.3389/fmed.2015.00080, PubMed 26618159

Gerdts E, Rossebø AB, Pedersen TR, Cioffi G, Lønnebakken MT, Cramariuc D, Rogge BP, Devereux RB (2015)
Relation of Left Ventricular Mass to Prognosis in Initially Asymptomatic Mild to Moderate Aortic Valve Stenosis
Circ Cardiovasc Imaging, 8 (11), e003644; discussion e003644
DOI 10.1161/CIRCIMAGING.115.003644, PubMed 26489804

Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, Henschien H, Fossen K, Markovic S, Pedersen TR, Sandvik L, Bragadóttir R (2015)
Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results
Ophthalmology, 123 (1), 51-9
DOI 10.1016/j.ophtha.2015.09.018, PubMed 26477842

Ikdahl E, Hisdal J, Rollefstad S, Olsen IC, Kvien TK, Pedersen TR, Semb AG (2015)
Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study
Arthritis Res Ther, 17, 279
DOI 10.1186/s13075-015-0795-y, PubMed 26445924

Strohmaier S, Røysland K, Hoff R, Borgan Ø, Pedersen TR, Aalen OO (2015)
Dynamic path analysis - a useful tool to investigate mediation processes in clinical survival trials
Stat Med, 34 (29), 3866-87
DOI 10.1002/sim.6598, PubMed 26278111

Rollefstad S, Ikdahl E, Hisdal J, Olsen IC, Holme I, Hammer HB, Smerud KT, Kitas GD, Pedersen TR, Kvien TK, Semb AG (2015)
Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study
Arthritis Rheumatol, 67 (7), 1718-28
DOI 10.1002/art.39114, PubMed 25778850

Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R et al. (2015)
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials
Eur Heart J, 36 (24), 1536-46
DOI 10.1093/eurheartj/ehv072, PubMed 25802390

Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR, Hovingh GK, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (2015)
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease
Heart, 101 (5), 356-62
DOI 10.1136/heartjnl-2014-306906, PubMed 25595417

Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A (2015)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials
Lancet, 385 (9976), 1397-405
DOI 10.1016/S0140-6736(14)61368-4, PubMed 25579834

Svendsen M, Tonstad S, Heggen E, Pedersen TR, Seljeflot I, Bøhn SK, Bastani NE, Blomhoff R, Holme IM, Klemsdal TO (2014)
The effect of kiwifruit consumption on blood pressure in subjects with moderately elevated blood pressure: a randomized, controlled study
Blood Press, 24 (1), 48-54
DOI 10.3109/08037051.2014.976979, PubMed 25483553

Cramariuc D, Rogge BP, Lønnebakken MT, Boman K, Bahlmann E, Gohlke-Bärwolf C, Chambers JB, Pedersen TR, Gerdts E (2014)
Sex differences in cardiovascular outcome during progression of aortic valve stenosis
Heart, 101 (3), 209-14
DOI 10.1136/heartjnl-2014-306078, PubMed 25301859

Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G et al. (2014)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
Lancet, 385 (9965), 351-61
DOI 10.1016/S0140-6736(14)61183-1, PubMed 25262344

Berg K, Pedersen TR, Sandvik L, Bragadóttir R (2014)
Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol
Ophthalmology, 122 (1), 146-52
DOI 10.1016/j.ophtha.2014.07.041, PubMed 25227499

Jander N, Hochholzer W, Kaufmann BA, Bahlmann E, Gerdts E, Boman K, Chambers JB, Nienaber CA, Ray S, Rossebo A, Pedersen TR, Wachtell K, Gohlke-Bärwolf C, Neumann FJ, Minners J (2014)
Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF
Heart, 100 (24), 1946-53
DOI 10.1136/heartjnl-2014-305763, PubMed 25217488

Green A, Ramey DR, Emneus M, Iachina M, Stavem K, Bolin K, McNally R, Busch-Sørensen M, Willenheimer R, Egstrup K, Kesäniemi YA, Ray S, Basta N, Kent C, Pedersen TR (2014)
Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial
Am J Cardiol, 114 (10), 1518-22
DOI 10.1016/j.amjcard.2014.08.016, PubMed 25267716

Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM, Ridker PM, Grundy SM, Kastelein JJ (2014)
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials
J Am Coll Cardiol, 64 (5), 485-94
DOI 10.1016/j.jacc.2014.02.615, PubMed 25082583

Minners J, Gohlke-Baerwolf C, Kaufmann BA, Bahlmann E, Gerdts E, Boman K, Chambers JB, Nienaber CA, Willenheimer R, Wachtell K, Holme I, Pedersen TR, Neumann FJ, Jander N (2014)
Adjusting parameters of aortic valve stenosis severity by body size
Heart, 100 (13), 1024-30
DOI 10.1136/heartjnl-2013-305225, PubMed 24780909

Rollefstad S, Ikdahl E, Hisdal J, Kvien TK, Pedersen TR, Holme I, Semb AG (2014)
Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention
Ann Rheum Dis, 74 (8), 1544-50
DOI 10.1136/annrheumdis-2013-204636, PubMed 24699940

STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD et al. (2014)
Darapladib for preventing ischemic events in stable coronary heart disease
N Engl J Med, 370 (18), 1702-11
DOI 10.1056/NEJMoa1315878, PubMed 24678955

Rogge BP, Gerdts E, Cramariuc D, Bahlmann E, Jander N, Gohlke-Bärwolf C, Pedersen TR, Lønnebakken MT (2014)
Impact of obesity and nonobesity on grading the severity of aortic valve stenosis
Am J Cardiol, 113 (9), 1532-5
DOI 10.1016/j.amjcard.2014.01.429, PubMed 24630788

Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I, Pedersen TR, IDEAL Investigators (2013)
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels
Int J Cardiol, 168 (4), 3846-52
DOI 10.1016/j.ijcard.2013.06.024, PubMed 24001698

Jander N, Gohlke-Bärwolf C, Bahlmann E, Gerdts E, Boman K, Chambers JB, Egstrup K, Nienaber CA, Pedersen TR, Ray S, Rossebø AB, Willenheimer R, Kienzle RP, Wachtell K, Neumann FJ, Minners J (2013)
Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis
Heart, 100 (1), 28-33
DOI 10.1136/heartjnl-2013-304443, PubMed 23969478

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM, Ridker PM, Kastelein JJ (2013)
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis
Circulation, 128 (14), 1504-12
DOI 10.1161/CIRCULATIONAHA.113.002670, PubMed 23965489

Skretteberg PT, Grytten AN, Gjertsen K, Grundvold I, Kjeldsen SE, Erikssen J, Mellbin L, Liestøl K, Fraser DA, Erikssen G, Pedersen TR, Bodegard J (2013)
Triglycerides-diabetes association in healthy middle-aged men: modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study
Diabetes Res Clin Pract, 101 (2), 201-9
DOI 10.1016/j.diabres.2013.06.001, PubMed 23827210

Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL (2013)
High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect
Circulation, 127 (25), 2485-93
DOI 10.1161/CIRCULATIONAHA.112.000712, PubMed 23674398

LaRosa JC, Pedersen TR, Somaratne R, Wasserman SM (2013)
Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events
Am J Cardiol, 111 (8), 1221-9
DOI 10.1016/j.amjcard.2012.12.052, PubMed 23375731

Rollefstad S, Kvien TK, Holme I, Eirheim AS, Pedersen TR, Semb AG (2012)
Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic
Ann Rheum Dis, 72 (12), 1968-74
DOI 10.1136/annrheumdis-2012-202789, PubMed 23264359

Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR (2012)
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes
J Am Coll Cardiol, 61 (2), 148-52
DOI 10.1016/j.jacc.2012.09.042, PubMed 23219296

Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I (2012)
Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease
Arthritis Rheum, 64 (9), 2836-46
DOI 10.1002/art.34524, PubMed 22576673

Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa J, Betteridge J, Pedersen TR, Holme I (2012)
Prediction of cardiovascular events in patients with ankylosing spondylitis and psoriatic arthritis: role of lipoproteins in a high-risk population
J Rheumatol, 39 (7), 1433-40
DOI 10.3899/jrheum.111307, PubMed 22660802

Holme I, Pedersen TR, Boman K, Egstrup K, Gerdts E, Kesäniemi YA, Malbecq W, Ray S, Rossebø AB, Wachtell K, Willenheimer R, Gohlke-Bärwolf C (2011)
A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis
Heart, 98 (5), 377-83
DOI 10.1136/heartjnl-2011-300475, PubMed 22155702

Arsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, DeMicco DA, Chatterjee A, Barter P, Deedwania P, Waters DD, LaRosa JC, Pedersen TR, Kastelein JJ, TNT and IDEAL Investigators (2011)
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies
Circ Cardiovasc Genet, 5 (1), 51-7
DOI 10.1161/CIRCGENETICS.111.960252, PubMed 22135385

Skretteberg PT, Grundvold I, Kjeldsen SE, Erikssen JE, Sandvik L, Liestøl K, Erikssen G, Pedersen TR, Bodegard J (2011)
HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men
Atherosclerosis, 220 (1), 250-6
DOI 10.1016/j.atherosclerosis.2011.10.009, PubMed 22062589

Greve AM, Gerdts E, Boman K, Gohlke-Baerwolf C, Rossebø AB, Nienaber CA, Ray S, Egstrup K, Pedersen TR, Køber L, Willenheimer R, Wachtell K (2011)
Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study
Int J Cardiol, 166 (1), 72-6
DOI 10.1016/j.ijcard.2011.09.064, PubMed 21996417

Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, Chambers JB, Egstrup K, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebø A, Pedersen TR, Skjærpe T, Willenheimer R, Wachtell K, Neumann FJ, Gohlke-Bärwolf C (2011)
Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction
Circulation, 123 (8), 887-95
DOI 10.1161/CIRCULATIONAHA.110.983510, PubMed 21321152

Olsson AG, Lindahl C, Holme I, Fayyad R, Faergeman O, Kastelein JJ, Tikkanen MJ, Larsen ML, Pedersen TR, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (2011)
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study
Eur J Cardiovasc Prev Rehabil, 18 (2), 262-9
DOI 10.1177/1741826710389391, PubMed 21450674

Gerdts E, Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber C, Ray S, Skjærpe T, Wachtell K, Willenheimer R (2010)
Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study)
Am J Cardiol, 106 (11), 1634-9
DOI 10.1016/j.amjcard.2010.07.042, PubMed 21094366

Semb AG, Holme I, Kvien TK, Pedersen TR (2010)
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial
Rheumatology (Oxford), 50 (2), 324-9
DOI 10.1093/rheumatology/keq295, PubMed 20884656

Pedersen TR, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Lindahl C, Szarek M (2010)
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
Am J Cardiol, 106 (3), 354-9
DOI 10.1016/j.amjcard.2010.03.033, PubMed 20643245

Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, Holme I (2010)
Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study
Ann Rheum Dis, 69 (11), 1996-2001
DOI 10.1136/ard.2009.126128, PubMed 20551156

Holme I, Boman K, Brudi P, Egstrup K, Gohlke-Baerwolf C, Kesäniemi YA, Malbecq W, Rossebø AB, Wachtell K, Willenheimer R, Pedersen TR (2010)
Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial
Am J Cardiol, 105 (12), 1802-8
DOI 10.1016/j.amjcard.2010.01.363, PubMed 20538134

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ et al. (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Lancet, 375 (9716), 735-42
DOI 10.1016/S0140-6736(09)61965-6, PubMed 20167359

Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR, IDEAL Investigators (2009)
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial
J Am Coll Cardiol, 54 (25), 2353-7
DOI 10.1016/j.jacc.2009.08.035, PubMed 20082922

Holme I, Fayyad R, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Holdaas H, Pedersen TR, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (2009)
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial
J Intern Med, 267 (6), 567-75
DOI 10.1111/j.1365-2796.2009.02176.x, PubMed 20141566

Mielniczuk LM, Pfeffer MA, Lewis EF, Blazing MA, de Lemos JA, Mohanavelu S, Rouleau J, Fox K, Pedersen TR, Califf RM (2009)
Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome
Clin J Am Soc Nephrol, 4 (11), 1811-7
DOI 10.2215/CJN.03510509, PubMed 19820133

Pedersen TR (2009)
Lipid-lowering drugs and risk for cancer
Curr Atheroscler Rep, 11 (5), 350-7
DOI 10.1007/s11883-009-0053-3, PubMed 19664378

Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJ, LaRosa JC, Larsen ML, Lindahl C, Olsson AG, Tikkanen MJ, Waters DD, Pedersen TR, Steering Committees of IDEAL and TNT Trials (2009)
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease
Am J Cardiol, 104 (4), 459-63
DOI 10.1016/j.amjcard.2009.04.008, PubMed 19660594

Klemsdal TO, Holme I, Nerland H, Pedersen TR, Tonstad S (2009)
Effects of a low glycemic load diet versus a low-fat diet in subjects with and without the metabolic syndrome
Nutr Metab Cardiovasc Dis, 20 (3), 195-201
DOI 10.1016/j.numecd.2009.03.010, PubMed 19502017

Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (2009)
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study
Eur J Cardiovasc Prev Rehabil, 16 (3), 315-20
DOI 10.1097/HJR.0b013e32832130f5, PubMed 19322096

Strandberg TE, Holme I, Faergeman O, Kastelein JJ, Lindahl C, Larsen ML, Olsson AG, Pedersen TR, Tikkanen MJ, IDEAL Study Group (2009)
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction
Am J Cardiol, 103 (10), 1381-5
DOI 10.1016/j.amjcard.2009.01.377, PubMed 19427432

Holme I, Strandberg TE, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (2009)
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)
Atherosclerosis, 205 (2), 522-7
DOI 10.1016/j.atherosclerosis.2009.01.023, PubMed 19327776

Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR, Incremental DEcrease through Aggressive Lipid Lowering Investigators (2009)
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)
Am J Cardiol, 103 (5), 577-82
DOI 10.1016/j.amjcard.2008.10.029, PubMed 19231315

Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators (2008)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
N Engl J Med, 359 (13), 1343-56
DOI 10.1056/NEJMoa0804602, PubMed 18765433

Steine K, Rossebø AB, Stugaard M, Pedersen TR (2008)
Left ventricular systolic and diastolic function in asymptomatic patients with moderate aortic stenosis
Am J Cardiol, 102 (7), 897-901
DOI 10.1016/j.amjcard.2008.07.001, PubMed 18805118

Pedersen TR (2008)
Intensive lipid-lowering therapy for patients with aortic stenosis
Am J Cardiol, 102 (11), 1571-6
DOI 10.1016/j.amjcard.2008.07.028, PubMed 19026317

Pedersen TR (2008)
Overview of clinical trials on calcific aortic stenosis
Eur. Heart J. Suppl., 10 (E), E31-E40
DOI 10.1093/eurheartj/sun014

Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM, TNT Study Group, IDEAL Study Group (2008)
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Circulation, 117 (23), 3002-9
DOI 10.1161/CIRCULATIONAHA.107.713438, PubMed 18519851

van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ (2008)
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies
J Am Coll Cardiol, 51 (6), 634-42
DOI 10.1016/j.jacc.2007.09.060, PubMed 18261682

Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR, Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group (2008)
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)
Ann Med, 40 (6), 456-64
DOI 10.1080/07853890801964955, PubMed 19160529

Catapano AL, Pedersen TR, de Backer G (2007)
Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management
Eur J Cardiovasc Prev Rehabil, 14 (2), 340-5
DOI 10.1097/hjr.0b013e3280122868, PubMed 17446817

Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J (2007)
Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency
Am J Kidney Dis, 49 (3), 373-82
DOI 10.1053/j.ajkd.2006.11.043, PubMed 17336698

Rossebø AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi VA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, Willenheimer R (2007)
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study
Am J Cardiol, 99 (7), 970-3
DOI 10.1016/j.amjcard.2006.10.064, PubMed 17398194

Pedersen TR (2006)
The gap between theory and practice: what do the trials tell us?
Eur. Heart J. Suppl., 8 (F), F10-F16
DOI 10.1093/eurheartj/sul035

Pedersen TR, Assmann G, Bassand JP, Chapman MJ, Erbel R, Sirtori C, European Expert Panel (2006)
Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment
Diab Vasc Dis Res, 3 (2), S1-S12
DOI 10.3132/dvdr.2006.011, PubMed 17083058

Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Grönhagen-Riska C, Neumayer HH, Maes B, Ambühl P, Hartmann A, Staffler B, Jardine AG, Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators (2005)
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study
Am J Transplant, 5 (12), 2929-36
DOI 10.1111/j.1600-6143.2005.01105.x, PubMed 16303007

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group (2005)
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
JAMA, 294 (19), 2437-45
DOI 10.1001/jama.294.19.2437, PubMed 16287954

Fellström B, Holdaas H, Jardine AG, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Staffler B, Pedersen TR, Assessment of Lescol in Renal Transplantation Study Investigators (2005)
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial
Transplantation, 79 (2), 205-12
DOI 10.1097/01.tp.0000147338.34323.12, PubMed 15665769

Retterstol L, Berge KE, Braaten Ø, Eikvar L, Pedersen TR, Sandvik L (2005)
A daily glass of red wine: does it affect markers of inflammation?
Alcohol Alcohol, 40 (2), 102-5
DOI 10.1093/alcalc/agh132, PubMed 15642722

Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR, Assessment of Lescol in Renal Transplantation Study Investigators (2004)
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial
Kidney Int, 66 (4), 1549-55
DOI 10.1111/j.1523-1755.2004.00919.x, PubMed 15458450

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (2004)
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
Am J Cardiol, 94 (6), 720-4
DOI 10.1016/j.amjcard.2004.06.003, PubMed 15374773

de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Investigators (2004)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial
JAMA, 292 (11), 1307-16
DOI 10.1001/jama.292.11.1307, PubMed 15337732

Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J, 4S Group (2004)
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)
Lancet, 364 (9436), 771-7
DOI 10.1016/S0140-6736(04)16936-5, PubMed 15337403

Pyörälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J, Scandinavian Simvastatin Survival Study (4S) (2004)
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)
Diabetes Care, 27 (7), 1735-40
DOI 10.2337/diacare.27.7.1735, PubMed 15220255

Jardine AG, Holdaas H, Fellström B, Cole E, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambühl P, Olsson AG, Holme I, Fauchald P, Gimpelwicz C, Pedersen TR, ALERT Study Investigators (2004)
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study
Am J Transplant, 4 (6), 988-95
DOI 10.1111/j.1600-6143.2004.00445.x, PubMed 15147434

Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M, 4S Group and the AFCAPS/TexCAPS Research Group (2004)
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Am J Cardiol, 93 (2), 136-41
DOI 10.1016/j.amjcard.2003.09.028, PubMed 14715336

Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR, Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators (2003)
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
Lancet, 361 (9374), 2024-31
DOI 10.1016/S0140-6736(03)13638-0, PubMed 12814712

Waehre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Frøland SS, Semb AG, Aukrust P (2003)
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease
J Am Coll Cardiol, 41 (9), 1460-7
DOI 10.1016/s0735-1097(03)00263-8, PubMed 12742282

Genest J, Pedersen TR (2003)
Prevention of cardiovascular ischemic events: high-risk and secondary prevention
Circulation, 107 (15), 2059-65
DOI 10.1161/01.CIR.0000067881.26274.BD, PubMed 12707251

Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Frøland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF (2003)
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy
J Am Coll Cardiol, 41 (2), 275-9
DOI 10.1016/s0735-1097(02)02718-3, PubMed 12535822

Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J (2001)
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
Circulation, 104 (25), 3046-51
DOI 10.1161/hc5001.100624, PubMed 11748098

Holdaas H, Fellström B, Holme I, Nyberg G, Fauchald P, Jardine A, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Weinreich T, Olsson AG, Pedersen TR, Benghozi R, Hartmann A, ALERT Study Group. Assessment of Lescol in Renal Transplantation (2001)
Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data
J Cardiovasc Risk, 8 (2), 63-71
DOI 10.1177/174182670100800202, PubMed 11324372

Pedersen TR (2001)
Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management
Am J Cardiol, 87 (5A), 8B-12B
DOI 10.1016/s0002-9149(01)01449-7, PubMed 11256850

Pedersen TR, Jahnsen KE, Vatn S, Semb AG, Kontny F, Zalmai A, Nerdrum T (2000)
Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study
Clin Ther, 22 (8), 949-60
DOI 10.1016/S0149-2918(00)80066-1, PubMed 10972631

Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyörälä K, Wedel H (2000)
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
Am J Cardiol, 86 (3), 257-62
DOI 10.1016/s0002-9149(00)00910-3, PubMed 10922429

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K (1999)
Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study
Arch Intern Med, 159 (22), 2661-7
DOI 10.1001/archinte.159.22.2661, PubMed 10597756

Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K (1999)
Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study
Diabetes Care, 22 (11), 1771-8
DOI 10.2337/diacare.22.11.1771, PubMed 10546006

Jönsson B, Cook JR, Pedersen TR (1999)
The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial
Diabetologia, 42 (11), 1293-301
DOI 10.1007/s001250051441, PubMed 10550412

Pedersen TR (1999)
Statin trials and goals of cholesterol-lowering therapy after AMI
Am Heart J, 138 (2 Pt 2), S177-82
DOI 10.1016/s0002-8703(99)70340-6, PubMed 10426879

Pedersen TR (1998)
Coronary artery disease: the Scandinavian Simvastatin Survival Study experience
Am J Cardiol, 82 (10B), 53T-56T
DOI 10.1016/s0002-9149(98)00727-9, PubMed 9860376

Faergeman O, Kjekshus J, Cook T, Pyörälä K, Wilhelmsen L, Thorgeirsson G, Pedersen TR (1998)
Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)
Eur Heart J, 19 (10), 1531-7
DOI 10.1053/euhj.1998.1191, PubMed 9820992

Pedersen TR (1998)
Aggressive lipid-lowering therapy: a clinical imperative
Eur Heart J, 19 Suppl M, M15-21
PubMed 9821012

Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ (1998)
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
Circulation, 97 (15), 1453-60
DOI 10.1161/01.cir.97.15.1453, PubMed 9576425

Pedersen TR (1998)
Prevention of cardiovascular disease: the Scandinavian experience
Aging (Milano), 10 (2), 167
PubMed 9666222

Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, Haghfelt T (1998)
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)
Am J Cardiol, 81 (3), 333-5
DOI 10.1016/s0002-9149(97)00904-1, PubMed 9468077

Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K (1997)
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease
J Card Fail, 3 (4), 249-54
DOI 10.1016/s1071-9164(97)90022-1, PubMed 9547437

Kontny F, Dale J, Abildgaard U, Pedersen TR (1997)
Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study
J Am Coll Cardiol, 30 (4), 962-9
DOI 10.1016/s0735-1097(97)00258-1, PubMed 9316525

Pyŏrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G (1997)
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Diabetes Care, 20 (4), 614-20
DOI 10.2337/diacare.20.4.614, PubMed 9096989

Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H (1997)
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group
N Engl J Med, 336 (5), 332-6
DOI 10.1056/NEJM199701303360503, PubMed 9011785

Pedersen TR (1996)
Primary prevention of cardiovascular disease: implications of lipid-lowering trials
J Hypertens Suppl, 14 (5), S195-200
PubMed 9120679

Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyörälä K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L (1996)
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
Arch Intern Med, 156 (18), 2085-92
DOI 10.1001/archinte.156.18.2085, PubMed 8862101

Kjekshus J, Pedersen TR, Tobert JA (1996)
Lipid-lowering therapy for patients with or at risk of coronary artery disease
Curr Opin Cardiol, 11 (4), 418-27
DOI 10.1097/00001573-199607000-00011, PubMed 8879953

Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H (1996)
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)
Eur Heart J, 17 (7), 1001-7
DOI 10.1093/oxfordjournals.eurheartj.a014994, PubMed 8809516

Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jönsson B, Schwartz JS (1996)
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study
Circulation, 93 (10), 1796-802
DOI 10.1161/01.cir.93.10.1796, PubMed 8635258

Pedersen TR, Tobert JA (1996)
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal
Drug Saf, 14 (1), 11-24
DOI 10.2165/00002018-199614010-00003, PubMed 8713485

Kjekshus J, Pedersen TR (1995)
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S)
Am J Cardiol, 76 (9), 64C-68C
DOI 10.1016/s0002-9149(99)80473-1, PubMed 7572690

Pedersen TR, Kantor M (1990)
Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol
Cardiovasc Drugs Ther, 4 (2), 451-6
DOI 10.1007/BF01857753, PubMed 2285629

Brubakk O, Pedersen TR, Overskeid K (1987)
Noninvasive evaluation of the effect of timolol on left ventricular performance after myocardial infarction and the consequence for prognosis
J Am Coll Cardiol, 9 (1), 155-60
DOI 10.1016/s0735-1097(87)80094-3, PubMed 3540070

Pedersen TR (1985)
Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction
N Engl J Med, 313 (17), 1055-8
DOI 10.1056/NEJM198510243131705, PubMed 2864634

Sirnes PA, Overskeid K, Pedersen TR, Bathen J, Drivenes A, Frøland GS, Kjekshus JK, Landmark K, Rokseth R, Sirnes KE (1984)
Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian Nifedipine Multicenter Trial
Circulation, 70 (4), 638-44
DOI 10.1161/01.cir.70.4.638, PubMed 6383655

Pedersen TR (1983)
The Norwegian Multicenter Study of Timolol after Myocardial Infarction
Circulation, 67 (6 Pt 2), I49-53
PubMed 6342838

Pedersen TR (1980)
[Hypertension treated with hydrochlorothiazide/amilorid and timolol maleate]
Tidsskr Nor Laegeforen, 100 (3), 150-53
PubMed 7385138

Review articles

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP et al. (2016)
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
Ann Rheum Dis, 76 (1), 17-28
DOI 10.1136/annrheumdis-2016-209775, PubMed 27697765

Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, Betteridge DJ, Bhatnagar D, Bilianou E, Carmena R, Ceška R, Corsini A, Erbel R, Flynn PD, Garcia-Moll X, Gumprecht J, Ishibashi S, Jambart S, Kastelein JJ, Maher V, da Silva PM, Masana L, Odawara M, Pedersen TR, Rotella CM et al. (2014)
The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice
Atheroscler Suppl, 15 (1), 1-15
DOI 10.1016/j.atherosclerosissup.2014.04.001, PubMed 24840509

Gohlke-Bärwolf C, Minners J, Jander N, Gerdts E, Wachtell K, Ray S, Pedersen TR (2013)
Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study
Curr Probl Cardiol, 38 (9), 365-409
DOI 10.1016/j.cpcardiol.2013.06.003, PubMed 23972937

Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ (2012)
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis
JAMA, 308 (8), 804-11
DOI 10.1001/jama.2012.8439, PubMed 22910758

Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Ridker PM, Kastelein JJ (2012)
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis
JAMA, 307 (12), 1302-9
DOI 10.1001/jama.2012.366, PubMed 22453571

Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK (2011)
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis
JAMA, 305 (24), 2556-64
DOI 10.1001/jama.2011.860, PubMed 21693744

Pedersen TR (2010)
Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering
Am J Cardiovasc Drugs, 10 Suppl 1, 10-7
DOI 10.2165/1158822-S0-000000000-00000, PubMed 21391729

Pedersen TR, Tobert JA (2004)
Simvastatin: a review
Expert Opin Pharmacother, 5 (12), 2583-96
DOI 10.1517/14656566.5.12.2583, PubMed 15571475

Rossebø AB, Pedersen TR (2004)
Hyperlipidaemia and aortic valve disease
Curr Opin Lipidol, 15 (4), 447-51
DOI 10.1097/01.mol.0000137229.00020.fe, PubMed 15243218

Waters D, Pedersen TR (1996)
Review of cholesterol-lowering therapy: coronary angiographic and events trials
Am J Med, 101 (4A), 4A34S-38S; discussion 39S
DOI 10.1016/s0002-9343(96)00318-x, PubMed 8900335

Pedersen TR (1995)
[Secondary prevention of coronary heart disease with lipid lowering drugs. Evaluating outcome eliminates the controversy]
Internist (Berl), 36 (12), 1174-8
PubMed 8567223